BRAF and melanoma: Pembrolizumab (MK-3475, formerly called Lambrolizumab) was FDA approved in September 2014 for use in relapsed or refractory malignant melanoma following treatment with Ipilimumab or after treatment with Ipilimumab and a BRAF inhibitor in patients who carry a BRAF mutation.